The ACR/CHEST ILD Guidelines in Practice: Register Now for This Informative Webinar

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hip OA

Technological Advances Linked to Medical Misadventures

  |  

For keen students of American politics, the unending intrigue of the 2016 presidential race has been riveting. With an assemblage of aspiring candidates that, at its start, included a bevy of U.S. senators and former governors, a media-savvy real estate mogul, a renowned Hopkins neurosurgeon and an ophthalmologist, political junkies among us have feasted on…

Practicing Mindfulness Can Help Alter Patients’ Experience With Chronic Rheumatic Diseases

Practicing Mindfulness Can Help Alter Patients’ Experience with Chronic Rheumatic Diseases

C. Ronald MacKenzie, MD  |  

Mindfulness is a mental state achieved by focusing one’s awareness on the present moment, while acknowledging and non-judgmentally accepting one’s feelings, thoughts and bodily sensations. Known in Sanskrit as smrti, meaning “to remember,” in Pali, the language of early Buddhist scriptures, it is recognized by the word sati (mindfulness).1 Derived from ancient meditative Buddhist disciplines,…

Rheumatology Research Foundation Creates Five-Year Strategic Plan

  |  

Dramatic advancements in research toward prevention and cure are at risk, as federal research funding for rheumatic diseases has declined by 40% over the past five years. With that, an alarming number of rheumatologists are preparing for retirement. To stop this worrying trend, a strategic plan for the next five years was developed to complement…

6 Tips for Writing a Good Clinical Case Report

  |  

“That’s a great case. Why don’t we write it up?” It’s a question I’ve heard many times throughout medical school, residency and fellowship. It’s typically intended to be more of a politely worded request than a rhetorical question. We must acknowledge that the process of writing, editing and submitting a case report is onerous, but it…

Rheumatology Coding Corner Answer: Coding & Billing Basics

  |  

Take the challenge. 1. D: All of the above Rationale: Per CPT, if time spent counseling and/or coordinating care dominates the session, then total time must be documented; greater than 50% of the time must be for face-to-face counseling and/or coordinating care, and must be documented as such. Additionally, the extent of the counseling and/or…

The ACR, ARHP Develop National Research Agenda for 2016–2020

  |  

Since 2005, the ACR’s Committee on Research has been responsible for advancing the research goals of the organization and providing leadership in research and research training in rheumatology via the ACR’s Research Agenda. The ACR Research Agenda is designed to address critical areas of research in rheumatic diseases, including the need for new technology, new…

Research Provides Insight into Impact of Microbiome on Health, Rheumatic Disease

Neha Ohri, MD, & Kristine A. Kuhn, MD, PhD  |  

The microbiome comprises diverse microbial flora, including bacteria, viruses and fungi, that live on mucosal surfaces, predominantly the skin and digestive tract. Microbes evolved billions of years prior to the development of modern Homo sapiens 200,000 years ago; we have always existed with their ubiquitous presence. Despite this, the first microbe was not visualized until…

Opinion: Politics Should Not Trump Science in Medicine

John A. Goldman, MD  |  

I tell my patients there are three types of science: 1) investigative science, which sometimes gets it right; 2) science in the courtroom, which is junk science; and 3) science in Washington, D.C., which is political science. Our decisions are based on art and science; our patients’ medications are brought to market based on science….

Biosimilars Debate Heats up over Cost Savings, Safety Concerns

Biosimilars Debate Heats up over Cost Savings, Safety Concerns

  |  

After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…